Addiction and corticotropin-releasing hormone type 1 receptor antagonist medications

Annals of the New York Academy of Sciences

Volumn 1282, Issue 1, 2013, Pages 107-118

  Contoreggi, Carlo ^a   Lee, Mary R ^b   Chrousos, George ^c  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Addiction; Corticotropin releasing hormone; CRH antagonists; Stress

Indexed keywords

3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; 4 AMINOBUTYRIC ACID; ALCOHOL; ANTALARMIN; CANNABIS; COCAINE; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; DOPAMINE; GLUTAMIC ACID; NICOTINE; OPIATE; SEROTONIN; UROCORTIN I; UROCORTIN II; UROCORTIN III;

ABSTINENCE; ADDICTION; ANXIETY; ARTICLE; CLINICAL EFFECTIVENESS; DEPRESSION; DRUG EFFICACY; DRUG EXPOSURE; EPIGENETICS; HUMAN; HYPOTHALAMUS; NEOCORTEX; NEUROPSYCHIATRY; OUTPATIENT CARE; STRESS; TREATMENT OUTCOME; VENTRAL TEGMENTUM;

EID: 84875848718     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12007     Document Type: Article

References (94)

1. Vale, W., J. Spiess, C. Rivier & J. Rivier. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 213: 1394-1397.
2. Chen, R.P., K.A. Lewis, M.H. Perrin & W.W. Vale. 1993. Expression cloning of a human corticotropin-releasing factor receptor. Proc. Natl. Acad. Sci. U. S. A. 90: 8967-8971.
3. Dautzenberg, F.M. & R.L. Hauger. 2002. The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol. Sci. 23: 71-77.
4. Hauger, R.L., D.E. Grigoriadis, M.F. Dallman, et al. 2003. International union of pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands. Pharmacol. Rev. 55: 21-26.
5. Grammatopoulos, D.K. 2012. Insights into mechanisms of corticotropin-releasing hormone receptor signal transduction. Br. J. Pharmacol. 166: 85-97. doi: 10.1111/j.1476-5381.2011.01631.x.
6. Perrin, M.H. & W.W. Vale. 1999. Corticotropin releasing factor receptors and their ligand family. Ann. N. Y. Acad. Sci. 885: 312-328.
7. Bale, T.L. & W.W. Vale. 2004. CRF and CRF receptors: role in stress responsivity and other behaviors. Annu. Rev. Pharmacol. Toxicol. 44: 525-557.
8. Liapakis, G., M. Venihaki, A. Margioris, et al. 2011. Members of CRF family and their receptors: from past to future. Curr. Med. Chem. 18: 2583-2600.
9. Chand, D & D.A. Lovejoy. 2011. Stress and reproduction: controversies and challenges. Gen. Comp. Endocrinol. 171: 253-257. [Epub 2011 Mar 22].
10. Denver, R.J. 2009. Structural and functional evolution of vertebrate neuroendocrine stress systems. Ann N. Y. Acad. Sci. 1163: 1-16.
11. Lovejoy, D.A. & R.J. Balment. 1999. Evolution and physiology of the corticotropin-releasing factor (CRF) family of neuropeptides in vertebrates. Gen. Comp. Endocrinol. 115: 1-22.
12. Lovejoy, D.A. & D. Barsyte-Lovejoy. 2010. Characterization of a corticotropin-releasing factor (CRF)/diuretic hormone-like peptide from tunicates: insight into the origins of the vertebrate CRF family. Gen. Comp. Endocrinol. 165: 330-336. [Epub 2009 Jul 29].
13. Pepels, P.P. & P.H. Balm. 2004. Ontogeny of corticotropin-releasing factor and of hypothalamic-pituitary-interrenal axis responsiveness to stress in tilapia (Oreochromis mossambicus; Teleostei). Gen. Comp. Endocrinol. 139: 251-265.
14. Primus, R.J., E. Yevich, C. Baltazar & D.W. Gallager. 1997. Autoradiographic localization of CRF1 and CRF2 binding sites in adult rat brain. Neuropsychopharmacology. 17: 308-316.
15. De Souza, E.B., T.R. Insel, M.H. Perrin, et al. 1985. Corticotropin-releasing factor receptors are widely distributed within the rat central nervous system: an autoradiographic study. J. Neurosci. 5: 3189-3203.
16. Millan, M.A., D.M. Jacobowitz, R.L. Hauger, et al. 1986. Distribution of corticotropin-releasing factor receptors in primate brain. Proc. Natl. Acad. Sci. U. S. A. 83: 1921-1925.
17. Habib, K.E., K.P. Weld, K.C. Rice, et al. 2000. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc. Natl. Acad. Sci. U. S. A. 97: 6079-6084.
18. Shalev, U., S. Erb & Y. Shaham. 2010. Role of CRF and other neuropeptides in stress-induced reinstatement of drug seeking. Brain Res. 1314: 15-28. [Epub 2009 Jul 23].
19. Shaham, Y., U. Shalev, L. Lu, et al. 2003. The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology (Berl). 168: 3-20. [Epub 2002 Oct 26].
20. Lu, L., J.D. Shepard, F.S. Hall & Y. Shaham. 2003. Effect of environmental stressors on opiate and psychostimulant reinforcement, reinstatement and discrimination in rats: a review. Neurosci. Biobehav. Rev. 27: 457-491.
21. Alheid, G.F. & L. Heimer. 1988. New perspectives in basal forebrain organization of special relevance for neuropsychiatric disorders: the striatopallidal, amygdaloid, and corticopetal components of substantia innominata. Neuroscience 27: 1-39.
22. Heimer, L., D.S. Zahm, L. Churchill, et al. 1991. Specificity in the projection patterns of accumbal core and shell in the rat. Neuroscience 41: 89-125.
23. Refojo, D., M. Schweizer, C. Kuehne, et al. 2011. Glutamatergic and dopaminergic neurons mediate anxiogenic and anxiolytic effects of CRHR1. Science 333: 1903-1907. [Epub 2011 Sep 1].
24. Unglessa, M.A., E. Argilli & A. Bonci. 2010. Effects of stress and aversion on dopamine neurons: implications for addiction. Neurosci. Biobehav. Rev. 35: 151-156
25. Mello, N.K., S.S. Negus, K.C. Rice & J.H. Mendelson. 2006. Effects of the CRF1 antagonist antalarmin on cocaine self-administration and discrimination in rhesus monkeys. Pharmacol. Biochem. Behav. 85: 744-751. [Epub 2006 Dec 19].
26. Brown, Z.J., E. Tribe, N.A. D'souza & S. Erb. 2009. Interaction between noradrenaline and corticotrophin-releasing factor in the reinstatement of cocaine seeking in the rat. Psychopharmacology (Berl). 203: 121-130. [Epub 2008 Nov 5].
27. Boyson, C.O., T.T. Miguel, I.M. Quadros, et al. 2011. Prevention of social stress-escalated cocaine self-administration by CRF-R1 antagonist in the rat VTA. Psychopharmacology (Berl). 218: 257-269. [Epub 2011 Apr 6].
28. Logrip, M.L., G.F. Koob & E.P. Zorrilla. 2011. Role of corticotropin-releasing factor in drug addiction: potential for pharmacological intervention. CNS Drugs 25: 271-287. doi: 10.2165/11587790-000000000-00000.
29. Kaur, S., J. Li, M.P. Stenzel-Poore & A.E. Ryabinin. 2012. Corticotropin-releasing factor acting on corticotropin-releasing factor receptor type 1 is critical for binge alcohol drinking in mice. Alcohol Clin. Exp. Res. 36: 369-376. doi: 10.1111/j.1530-0277.2011.01610.x. [Epub 2011 Sep 6].
30. Chu, K., G.F. Koob, M. Cole, et al. 2007. Dependence-induced increases in ethanol self-administration in mice are blocked by the CRF1 receptor antagonist antalarmin and by CRF1 receptor knockout. Pharmacol. Biochem. Behav. 86: 813-821. [Epub 2007 Apr 3].
31. Cippitelli, A., R. Damadzic, E. Singley, et al. 2012. Pharmacological blockade of corticotropin-releasing hormone receptor 1 (CRH1R) reduces voluntary consumption of high alcohol concentrations in non-dependent Wistar rats. Pharmacol. Biochem. Behav. 100: 522-529. [Epub 2011 Oct 20].
32. Wong, C.C., J. Mill & C. Fernandes. 2011. Drugs and addiction: an introduction to epigenetics. Addiction 106: 480-489
33. Bali, P., H.I. Im & P.J. Kenny. 2011. Methylation, memory and addiction. Epigenetics 6: 671-674. [Epub 2011 Jun 1].
34. Lester, B.M., E. Tronick, E. Nestler, et al. 2011. Behavioral epigenetics. Ann. N. Y. Acad. Sci. 1226: 14-33.
35. Zhou, Y., D. Proudnikov, V. Yuferov & M.J. Kreek. 2010. Drug-induced and genetic alterations in stress-responsive systems: implications for specific addictive diseases. Brain Res. 1314: 235-252. [Epub 2009 Nov 12].
36. Briand, L.A. & J.A. Blendy. 2010. Molecular and genetic substrates linking stress and addiction. Brain Res. 1314: 219-234. [Epub 2009 Nov 10].
37. Wang, S.S., W. Kamphuis, I. Huitinga, et al. 2008. Gene expression analysis in the human hypothalamus in depression by laser microdissection and real-time PCR: the presence of multiple receptor imbalances. Mol. Psychiatry 13: 786-799, 741. [Epub 2008 Apr 22].
38. Skelton, K.H., D.A. Gutman, K.V. Thrivikraman, et al. 2007. The CRF1 receptor antagonist R121919 attenuates the neuroendocrine and behavioral effects of precipitated lorazepam withdrawal. Psychopharmacology (Berl). 192: 385-396. [Epub 2007 Feb 13].
39. Skelton, K.H., D. Oren, D.A. Gutman, et al. 2007. The CRF1 receptor antagonist, R121919, attenuates the severity of precipitated morphine withdrawal. Eur. J. Pharmacol. 571: 17-24. [Epub 2007 Jun 5].
40. Zhang, Y., H. Hong & W. Cai. 2011. PET tracers based on Zirconium-89. Curr. Radiopharm. 4: 131-139.
41. Brogan, J., F. Li, W.Li, et al. 2012. Imaging molecular pathways: reporter genes. Radiat Res. 177: 508-513. [Epub 2012 Feb 21].
42. Smith, T.A. 2010. Towards detecting the HER-2 receptor and metabolic changes induced by HER-2-targeted therapies using medical imaging. Br. J. Radiol. 83: 638-644.
43. Tung, J., L.B. Barreiro, Z.P. Johnson, et al. 2012. Social environment is associated with gene regulatory variation in the rhesus macaque immune system. Proc. Natl. Acad. Sci. U. S. A. 109: 6490-6495. [Epub 2012 Apr 9].
44. Sapolsky, R.M. 2004. Social status and health in humans and other animals. Annu. Rev. Anthropol. 33: 393-418.
45. Sapolsky, R.M. 2005. The influence of social hierarchy on primate health. Science 308: 648-652.
46. Andersen, S.L., A. Tomada, E.S. Vincow, et al. 2008. Preliminary evidence for sensitive periods in the effect of childhood sexual abuse on regional brain development. J. Neuropsychiatry Clin. Neurosci. 20: 292-301.
47. Ressler, K.J., B. Bradley, K.B. Mercer, et al. 2010. Polymorphisms in CRHR1 and the serotonin transporter loci: gene x gene x environment interactions on depressive symptoms. Am. J. Med. Genet B Neuropsychiatr Genet. 153B: 812-824.
48. Grabe, H.J., C. Schwahn, K. Appel, et al. 2010. Childhood maltreatment, the corticotropin-releasing hormone receptor gene and adult depression in the general population. Am. J. Med. Genet B Neuropsychiatr Genet. 153B: 1483-1493. doi: 10.1002/ajmg.b.31131. [Epub 2010 Oct 18].
49. Andersen, S.L. & M.H. Teicher. 2008. Stress, sensitive periods and maturational events in adolescent depression. Trends Neurosci. 31: 183-191. [Epub 2008 Mar 10].
50. Wasserman, D., J. Wasserman, V. Rozanov & M. Sokolowski. 2009. Depression in suicidal males: genetic risk variants in the CRHR1 gene. Genes Brain Behav. 8: 72-79.
51. Taqi, M.M., I. Bazov, H. Watanabe, et al. 2011. Prodynorphin CpG-SNPs associated with alcohol dependence: elevated methylation in the brain of human alcoholics. Addict Biol. 16: 499-509. doi: 10.1111/j.1369-1600.2011.00323.x. [Epub 2011 Apr 26].
52. Nemeroff, C.B., M.J. Owens, G. Bissette, et al. 1988. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch. Gen. Psychiatry. 45: 577-579.
53. Merali, Z., L. Du, P. Hrdina, et al. 2004. Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region. J. Neurosci. 24: 1478-1485.
54. Poulter, M.O., L. Du, I.C. Weaver, et al. 2008. GABAA receptor promoter hypermethylation in suicide brain: implications for the involvement of epigenetic processes. Biol. Psychiatry 64: 645-652. [Epub 2008 Jul 18].
55. Sequeira, A., F. Mamdani, C. Ernst, et al. 2009. Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression. PLoS One. 4: e6585.
56. Enoch, M.A., Z. Zhou, M.Kimura, et al. 2012. GABAergic gene expression in postmortem hippocampus from alcoholics and cocaine addicts; corresponding findings in alcohol-naïve P and NP Rats. PLoS One. 7: e29369. [Epub 2012 Jan 13].
57. Schmid, B., D. Blomeyer, J. Treutlein, et al. 2010. Interacting effects of CRHR1 gene and stressful life events on drinking initiation and progression among 19-year-olds. Int. J. Neuropsychopharmacol. 13: 703-714. [Epub 2009 Jul 17].
58. Sinha, R. 2011. New findings on biological factors predicting addiction relapse vulnerability. Curr. Psychiatry Rep. 13: 398-405.
59. Sinha, R., H.C. Fox, K.I. Hong, et al. 2011. Effects of adrenal sensitivity, stress- and cue-induced craving, and anxiety on subsequent alcohol relapse and treatment outcomes. Arch. Gen. Psychiatry. 68: 942-952. doi: 10.1001/archgenpsychiatry.2011.49. [Epub 2011 May 2].
60. Sinha, R., M. Talih, R. Malison, et al. 2003. Hypothalamic-pituitary adrenal axis and sympatho-adreno-medullary responses during stress-induced and drug cue-induced cocaine craving states. Psychopharmacology (Berl). 170: 62-72.
61. Breese, G.R., K. Chu, C.V. Dayas, et al. 2005. Stress enhancement of craving during sobriety and the risk of relapse. Alcohol Clin. Exp. Res. 29: 185-195.
62. al'Absi, M., D. Hatsukami & G.L. Davis. 2005. Attenuated adrenocorticotropic responses to psychological stress are associated with early smoking relapse. Psychopharmacology (Berl). 181: 107-117. [Epub 2005 Apr 15].
63. Contoreggi, C., R.I. Herning, P. Na, et al. 2003. Stress hormone responses to corticotropin-releasing hormone in substance abusers without severe comorbid psychiatric disease. Biol. Psychiatry. 54: 873-878.
64. Contoreggi, C., R.I. Herning, B. Koeppl, et al. 2003. Treatment-seeking inpatient cocaine abusers show hypothalamic dysregulation of both basal prolactin and cortisol secretion. Neuroendocrinology. 78: 154-162.
65. Waldrop, A.E., K.L. Price, S.M. Desantis, et al. 2010. Community-dwelling cocaine-dependent men and women respond differently to social stressors versus cocaine cues. Psychoneuroendocrinology 35: 798-806. [Epub 2009 Dec 9].
66. Koob, G.F. 2010. The role of CRF and CRF-related peptides in the dark side of addiction. Brain Res. 1314C: 3. doi: 10.1016/j.brainres.2009.11.008
67. Zobel, A.W., T. Nickel, H.E. Künzel, et al. 2000. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatr. Res. 34: 171-181.
68. Koob, GF & E.P. Zorrilla. 2012. Update on corticotropin-releasing factor pharmacotherapy for psychiatric disorders: a revisionist view. Neuropsychopharmacology Rev. 37: 308-309;
69. Walsh, B.T., S.N. Seidman, R. Sysko & M. Gould. 2002. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 287: 1840-1847.
70. Kemp, A.S., N.R. Schooler, A.H. Kalali, et al. 2010. What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophr Bull. 36: 504-509. [Epub 2008 Aug 22].
71. Guess, H.A., A. Kleinman, J.W. Kusek & L.W. Engel, Eds. 2002. The science of the placebo: toward an interdisciplinary research agenda. BMJ 324: 1460.
72. Fleck, B.A., S.R. Hoare, R.R. Pick, et al. 2012. Binding kinetics redefine the antagonist pharmacology of the corticotropin-releasing factor type 1 receptor. J. Pharmacol Exp. Ther. 341: 518-531. [Epub 2012 Feb 22].
73. Ramsey, S.J., N.J. Attkins, R. Fish & P.H. van der Graaf. 2011. Quantitative pharmacological analysis of antagonist binding kinetics at CRF1 receptors in vitro and in vivo. Br. J. Pharmacol. 164: 992-1007.
74. Ising, M., U.S. Zimmermann, H.E. Künzel, et al. 2007. High-affinity CRF(1) receptor antagonist NBI-34041: preclinical and clinical data suggest safety and efficacy in attenuating elevated stress response. Neuropsychopharmacology 32: 1949.
75. Foley, P. & C. Kirschbaum. 2011. Human hypothalamus-pituitary-adrenal axis responses to acute psychosocial stress in laboratory settings. Neurosci. Biobehav Rev. 35: 91-96.
76. Brigitte, M.K. & S. Wüst. 2010. Human models in acute and chronic stress: Assessing determinants of individual hypothalamus-pituitary-adrenal axis activity and reactivity. Stress 13: 1-14
77. Jobes, M.L., U.E. Ghitza, D.H. Epstein, et al. 2011. Clonidine blocks stress-induced craving in cocaine users. Psychopharmacology (Berl). 218: 83-88. [Epub 2011 Mar 12].
78. Sinha, R., T. Fuse, L.R. Aubin & S.S. O'Malley. 2000. Psychological stress, drug-related cues and cocaine craving. Psychopharmacology (Berl). 152: 140-148.
79. Grant, S., E.D. London, D.B. Newlin, et al. 1996. Activation of memory circuits during cue-elicited cocaine craving. Proc. Natl. Acad. Sci. U. S. A. 93: 12040-12045.
80. Heinz, A., T. Siessmeier, J. Wrase, et al. 2004. Correlation between dopamine D(2) receptors in the ventral striatum and central processing of alcohol cues and craving. Am. J. Psychiatry. 161: 1783-1789.
81. Volkow, N.D., G.J. Wang, F. Telang, et al. 2006. Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction. J. Neurosci. 26: 6583-6588.
82. Wong, D.F., H. Kuwabara, D.J. Schretlen, et al. 2006. Increased occupancy of dopamine receptors in human striatum during cue-elicited cocaine craving. Neuropsychopharmacology. 31: 2716-2727.
83. Sinha, R. & C.S. Li. 2007. Imaging stress- and cue-induced drug and alcohol craving: association with relapse and clinical implications. Drug Alcohol Rev. 26: 25-31.
84. Potenza, M.N., K.I. Hong, C.M. Lacadie, et al. 2012. Neural correlates of stress-induced and cue-induced drug craving: influences of sex and cocaine dependence. Am. J. Psychiatry. 169: 406-414.
85. Schmidt, M.E., R.D. Andrews, P. van der Ark, et al. 2010. Dose-dependent effects of the CRF(1) receptor antagonist R317573 on regional brain activity in healthy male subjects. Psychopharmacology (Berl). 208: 109-119. [Epub 2009 Nov 13].
86. Hubbard, C.S., J.S.Labus, J. Bueller, et al. 2011. Corticotropin-releasing factor receptor 1 antagonist alters regional activation and effective connectivity in an emotional-arousal circuit during expectation of abdominal pain. J. Neurosci. 31: 12491-1500.
87. Eckelman, W.C., K.C. Rice & C. Contoreggi. 2004. New tools to monitor stress using non-invasive PET imaging. Ann. N. Y. Acad. Sci. 1018: 487-494.
88. Gottardo, R., A. Fanigliulo, D. Sorio, et al. 2012. Monitoring compliance to therapy during addiction treatments by means of hair analysis for drugs and drug metabolites using capillary zone electrophoresis coupled to time-of-flight mass spectrometry. Forensic Sci. Int. 216: 101-107.
89. Epstein, D.H., K.L. Preston. 2010. Daily life hour by hour, with and without cocaine: an ecological momentary assessment study. Psychopharmacology (Berl). 211: 223-232. [Epub 2010 Jun 9].
90. Epstein, D.H., G.F. Marrone, S.J. Heishman, et al. 2010. Tobacco, cocaine, and heroin: craving and use during daily life. Addict. Behav. 35: 318-324. [Epub 2009 Nov 12].
91. Preston, K.L. & D.H. Epstein. 2011. Stress in the daily lives of cocaine and heroin users: relationship to mood, craving, relapse triggers, and cocaine use. Psychopharmacology (Berl). 218: 29-37. [Epub 2011 Feb 12].
92. Johnson, B.A., K. Mann, M. L. Willenbring, et al. 2005. Challenges and opportunities for medications development in alcoholism: an international perspective on collaborations between academia and industry. Alcohol Clin. Exp. Res. 29: 1528-1540.
93. Kreek, M.J., K.S. LaForge & E. Butelman. 2002. Pharmacotherapy of addictions. Nat. Rev. Drug Discov. 1: 710-726.
94. Yang, H., C. Cusin & M. Fava. 2005. Is there a placebo problem in antidepressant trials? Curr. Top. Med. Chem. 5: 1077-1086.